- |||||||||| Unimolecular multiagonists (dual and triple) for the management of obesity and cardiorenal risk (Hall A8) - Dec 16, 2022 - Abstract #ATTD2023ATTD_25;
Inthe T2D phase 3 SURPASS clinical development program, tir-zepatide at 5, 10 and 15 mg once weekly demonstrated unprece-dented glycemic and weight control across the spectrum of thedisease, exceeding that seen with once-weekly semaglutide 1.0 mg(SURPASS-2) and titrated insulin degludec (SURPASS-3)...As we look into the future, these importantagents that address obesity and its many complications (includingdysglycemia) should gain increasing prominence in our manage-ment of metabolic diseases. We await further weight loss data aswell as data demonstrating potential cardiorenal benefits.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Byetta (exenatide) / AstraZeneca
GLP-1 Analogs for the treatment of obesity (Hall A8) - Dec 16, 2022 - Abstract #ATTD2023ATTD_24; Short-term preconception intervention with exena-tide resulted in an increase of natural pregnancy rates in over-weightandobesewomenwithPCOS.Apilotstudyshowedthatpreconception treatment with liraglutide increased pregnancyrates for patients with PCOS undergoing in vitro fertilizationwho responded poorly to first line reproductive treatment...The great advances are being seen in the use of GLP-1 re-ceptor agonists in combination with multi-agonist unimolecularpeptides, such as glucose dependent insulinotropic polypeptide(GIP), gastrin, amylin analogue, and others. GLP-1 RAs andother developing therapeutic tools will change the way cliniciansapproach obesity and the prognosis of many ABCDs.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P2 trial: The SLIM LIVER Study (clinicaltrials.gov) - Dec 16, 2022 P2, N=51, Active, not recruiting,
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes. (Pubmed Central) - Nov 22, 2022 The once-daily glucagon-like peptide 1 (GLP-1) analogue, liraglutide has been shown to reduce major adverse cardiovascular events (MACE) and progression of chronic kidney disease (CKD)...Such favorable metabolic changes by oral semaglutide were observed more prominently in patients who had not ever used GLP-1 analogues than in patients who switched from subcutaneous GLP-1 analogues. Our study showed that oral semaglutide improved body weight, blood pressure, HbA1c, LDL-C, non-HDL-C and UACR, in type 2 diabetic obese patients, especially, in patients who had not ever used GLP-1 analogues.
- |||||||||| Journal: Drugs for type 2 diabetes. (Pubmed Central) - Nov 18, 2022
Our study showed that oral semaglutide improved body weight, blood pressure, HbA1c, LDL-C, non-HDL-C and UACR, in type 2 diabetic obese patients, especially, in patients who had not ever used GLP-1 analogues. No abstract available
|